Proarrhythmic effects of four class III antiarrhythmic drugs, MS-551, sematilide, dofetilide and KCB328, examined using ambulatory ECG

Asia Pacific Journal of Pharmacology

Volumn 14, Issue 3, 2000, Pages 101-109

  Akie, Y ^a   Ni, C ^a   Aye, N N ^a   Xue, Y X ^a   Hashimoto, K ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Ambulatory ECG; Antiarrhythmic agent; K+ channel blocker; Old myocardial infarction; Proarrhythmic effect

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; N [3 AMINO 4 [2 [N (3,4 DIMETHOXYPHENETHYL) N METHYLAMINO]ETHOXY]PHENYL]METHANESULFONAMIDE; NIFEKALANT; SEMATILIDE;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART RATE; MALE; NONHUMAN; QT INTERVAL; TORSADE DES POINTES;

EID: 0033792284     PISSN: 02179687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ventricular premature beats and mortality after myocardial infarction
2. Preliminary report: Effect of encaimide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
3. Amiodarone: Electropharmacologic properties
4. Class III antiarrhythmic action
5. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions
6. Effects of the new class III antiarrhythmic drug MS-551 and d-Sotalol on Canine Coronary Ligation Reperfusion Ventricular arrhythmias
7. Electrophysiological effects of bretylium tosylate on single fibers of canine specialized conduction system and ventricle
8. The effect of bretylium tosylate on the electrophysiological properties of ventricular muscle and Purkinje fibers
9. Electrophysiological effects of bretylium tosylate on the heart
10. The effect of amiodarone, a new antiangina drug, on cardiac muscle
11. Electrophysiological effects of amiodarone: Experimental and clinical observation relative to serum and tissue drug concentrations
12. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials and other pharmacological actions on cardiac muscle of MJ 1999 and AH 3474
13. Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence
14. Reverse use-dependent effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle
15. Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia
16. Study of the ambulatory ECG on the dog. I. Lead method and jacket putting applied to the ambulatory ECG recording
17. Antiarrhythmic effect and haemodynamic agent, in anaesthetized dogs
18. The ESVEM trial; electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias
19. Determinants of predicted antiarrhythmic drugs in the Electrophysiologic Study Versus Electrocardiographic Monitoring Trial
20. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias
21. Antiarrhythmic effects of Na+/H+ exchange inhibitors